Diligence memo · auto-generated · as of July 2, 2026
Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Outlook Therapeutics, Inc. operates in Biotechnology, based in ISELIN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Outlook Therapeutics, Inc. has raised $213M in disclosed capital across 12 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $60M on 2024-03-18.
Most recent recorded round closed around 2025-01-17.
Valuation (modeled)modeled
Provath models Outlook Therapeutics, Inc. at approximately $232M (range $99M–$326M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.20× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era. Within the normal band (120% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 6.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Biotechnology peers (4293 compared).
Modeled value ranks above 74% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.